Buy & Sell Incyte Corporation (INCY) – Incyte Corporation Price Today
Aura AI Summary
Key Stats
- $21.54BMarket Cap
- HealthSector
- -8.05%3M Drawdown
- $17.57BEnterprise Value
- -Dividend Yield
- 3% Buy | 97% SellTrading Activity
- 29 daysTypical Hold Time
Incyte Corporation (INCY) is currently valued at a market capitalization of $21.54B, with an enterprise value of $17.57B. Over the past 52 weeks, Incyte Corporation has traded between a low of $67.26 and a high of $110.57, highlighting its annual price range. Over the past three months, Incyte Corporation has recorded a drawdown of -8.05%, reflecting recent price volatility. On average, investors hold Incyte Corporation for approximately 29 days, indicating typical investor behavior on the platform.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Most Recent News
Investors back Elon Musk's vision as SpaceX IPO focuses on future potential over near-term profits
Investors are optimistic about SpaceX's IPO, focusing on Elon Musk's proven ability to turn ambitious visions into reality rather than short-term earnings. Nancy Tengler highlights Musk's history of overcoming near-disasters with Tesla and SpaceX, an...

UniFirst shareholders approve merger with Cintas, deal expected to close in late 2026.
UniFirst shareholders overwhelmingly approved the company's acquisition by Cintas, with over 99% of votes in favor, representing about 95% of all shares. Under the deal, UniFirst shareholders will receive $155 in cash plus 0.7720 shares of Cintas sto...

Conflict minerals from Congo reportedly enter supply chains of NVIDIA, Microsoft, raising ethical concerns.
A report by Global Witness reveals that conflict minerals, specifically coltan from the Democratic Republic of the Congo, have infiltrated the supply chains of major tech companies including NVIDIA and Microsoft. Coltan, essential for electronics cap...
